Literature DB >> 8675153

Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis.

K M Boberg1, O Fausa, T Haaland, E Holter, O J Mellbye, A Spurkland, E Schrumpf.   

Abstract

Overlapping features between primary sclerosing cholangitis (PSC and autoimmune hepatitis (AIH) have previously been noted. To assess systematically similarities between these disorders, we have evaluated 114 PSC patients (36 women; 78 men), all confirmed by endoscopic retrograde cholangiography (ERC), according to a scoring system proposed by The International Autoimmune Hepatitis Group for the diagnosis of AIH. The scoring system attributes positive or negative scores to the parameters sex, ratio of elevation of serum levels of alkaline phosphatase (ALP) vs. aminotransferase, serum levels of immunoglobulins and autoantibodies, viral markers, history of drug and alcohol intake, genetic factors, liver histology, and response to therapy. Two of the PSC patients (2%) obtained scores above 15 before treatment, satisfying the diagnostic criterion of "definite" AIH. Thirty-eight patients (33%) scored between 10 and 15 points and could be classified as "probable" AIH. The serum level of immunoglobulin G (IgG) was elevated in 68 patients (61% of 111 cases tested), and positive titers of antinuclear antibodies (ANA) or smooth muscle antibodies (SMA) were detected in 24 patients (22% of 111 cases tested). Thirty-five of the PSC patients (33% of 105 evaluable biopsy specimens) obtained positive scores for histological features similar to those of AIH, but the total score for histology was in the negative range in 72 patients (69%) because of the presence of biliary changes. The frequent finding of high scores in PSC patients underlines the similarities PSC may have with AIH. A modification of the scoring system, in particular by increasing the negative score for histological biliary changes, would improve its potential to discriminate between AIH and PSC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675153     DOI: 10.1002/hep.510230612

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 3.  Primary sclerosing cholangitis: is any treatment worthwhile?

Authors:  Ashley Barnabas; Roger W Chapman
Journal:  Curr Gastroenterol Rep       Date:  2012-02

Review 4.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 5.  Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.

Authors:  Ersilia M DeFilippis; Sonal Kumar
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

6.  Performance parameters of the conventional serological markers for autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-12-03       Impact factor: 3.199

Review 7.  Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease.

Authors:  Rebecca Saich; Roger Chapman
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 8.  Diagnosis and management of the overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Can J Gastroenterol       Date:  2013-07       Impact factor: 3.522

Review 9.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

Review 10.  Overlap syndromes of autoimmune hepatitis: what is known so far.

Authors:  Marilena Durazzo; Alberto Premoli; Sharmila Fagoonee; Rinaldo Pellicano
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.